- Enzon Pharmaceuticals, Inc. (OTC:ENZN) undergoes a reverse stock split at a ratio of 100 for 1 to consolidate shares and enhance marketability.
- The reverse stock split will be effective from March 24, 2026, with ENZN’s stock trading under the temporary symbol “ENZND” for 20 trading days.
- ENZN aims to improve its stock’s appeal to investors and align its share price with market expectations through this strategic move.
Enzon Pharmaceuticals, Inc. (OTC:ENZN) is a company that operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutics. On March 25, 2026, ENZN underwent a significant change with a reverse stock split at a ratio of 100 for 1. This move is part of the company’s strategy to consolidate its shares and potentially enhance its stock’s marketability.
The reverse stock split, effective March 24, 2026, at 4:30 pm Eastern Time, consolidates every 100 shares of ENZN’s common stock into a single share. This adjustment will be reflected in the trading of ENZN’s stock on the OTCQB market starting March 25, 2026. For 20 trading days, the stock will trade under the temporary symbol “ENZND,” as highlighted by the company’s announcement.
ENZN’s current stock price is $0.06, with fluctuations during the day ranging from a low of $0.04 to a high of $0.06. Over the past year, the stock has seen a high of $0.13 and a low of $0.02. The reverse stock split aims to address these fluctuations by reducing the number of shares outstanding, potentially leading to a higher stock price per share.
The company’s market capitalization is approximately $4.45 million, and today’s trading volume is 207,734 shares. By implementing the reverse stock split, ENZN seeks to improve its stock’s appeal to investors and align its share price with market expectations. No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive a proportional cash payment.
